PDB54 - ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLAND
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.759
https://www.valueinhealthjournal.com/article/S1098-3015(18)34059-2/fulltext
Section Title :
Section Order :
162
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34059-2&doi=10.1016/j.jval.2018.09.759